Lung cancer is a widespread disease which is more typical for smokers. In about 8 out of 10 cases lung cancer develops in people who are over 60. Lung cancer can be central and peripheral. According to histologic structure there are 2 big groups: non-small-cell and small-cell lung cancer. The major factor of the disease risk is smoking – probability of death from lung cancer is 8 times higher in people who smoke 1-14 cigarettes a day, in comparison with non-smokers.
For central lung cancer most typical are the following symptoms: cough (dry or with bloody phlegm); frequent pneumonias occurring withoutevident reasons (pneumonites); pain in the chest (usually in the area damaged by cancer); high body temperature; breath disorder (short wind)
Intrusive diagnostics:needle biopsy of lung tumors under CCT with the subsequent histological, cytological and immunohistochemicalexamination.
Non-intrusive diagnostics: Computer tomography of the chest and mediastinum organs. Diagnostics of lung cancer makes it possible to determine not only primary cancer but also metastases (including plural metastases) with the subsequent multiplanar reconstruction of the centers the size of which is one millimeter (1 mm) and more.
Treatment of the patients with lung cancer includes all methods accepted in modern clinical oncology: surgical, radial, chemotherapeutic and their various combinations. If lung cancer is diagnosed at early stages, there is a chance of its treatment by means of CyberKnife - the system of tracking Cyberknife Synchrony makes it possible to irradiate a moving object — lung tumor with high accuracy without X-ray contrasting markers preliminary inserted in the tumor; thus the error makes less than 0,5 millimeters. High accuracy of treatment minimizes the risk of occurrence of general reactions andpostradiation lung fibrosis. The use of CyberKnifeshould become a standard in the treatment of initial stages of non-small-cell lung cancer and improve the indicator of 5-year-old recoveries as well as the quality of life of patients with lung cancer.